Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Ham, Hyoungjun ^a   Billadeau, Daniel D ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Cytotoxic lymphocytes; Cytotoxic synapse; Lytic granules; NK cell cytotoxicity; NK cells; Primary immunodeficiency

Indexed keywords

F ACTIN; MYOSIN; MYOSIN IIA; N ETHYLMALEIMIDE SENSITIVE FACTOR;

APOPTOSIS; BIOGENESIS; CELL KILLING; CHEDIAK HIGASHI SYNDROME; CYTOKINESIS; CYTOLYSIS; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; EXOCYTOSIS; GENE MUTATION; GRISCELLI SYNDROME; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY; MICROTUBULE; NATURAL KILLER CELL; NONHUMAN; OCULAR ALBINISM; PAPILLON LEFEVRE SYNDROME; REVIEW; WISKOTT ALDRICH SYNDROME;

EID: 84895531658     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00002     Document Type: Review

References (237)

1. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev (2007) 220:169-82. doi:10.1111/j.1600-065X.2007.00563.x.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9(5):503-10. doi:10.1038/ni1582.
3. Caligiuri MA. Human natural killer cells. Blood (2008) 112(3):461-9. doi:10.1182/blood-2007-09-077438.
4. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol (2011) 12(6):500-8. doi:10.1038/ni.2032.
5. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331(6013):44-9. doi:10.1126/science.1198687.
6. Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol (2008) 20(3):344-52. doi:10.1016/j.coi.2008.03.005.
7. Lanier LL. NK cell recognition. Annu Rev Immunol (2005) 23:225-74. doi:10.1146/annurev.immunol.23.021704.115526.
8. Watzl C, Urlaub D. Molecular mechanisms of natural killer cell regulation. Front Biosci (Landmark Ed) (2012) 17:1418-32. doi:10.2741/3995.
9. Karre K. Natural killer cell recognition of missing self. Nat Immunol (2008) 9(5):477-80. doi:10.1038/ni0508-477.
10. Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol (2006) 18(3):145-50. doi:10.1016/j.smim.2006.03.003.
11. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, et al. Molecular mechanisms of natural killer cell activation. J Innate Immun (2011) 3(3):216-26. doi:10.1159/000325265.
12. Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol (2010) Chapter 11:Unit 11.9B. doi:10.1002/0471142735.im1109bs90.
13. Dustin ML, Long EO. Cytotoxic immunological synapses. Immunol Rev (2010) 235(1):24-34. doi:10.1111/j.0105-2896.2010.00904.x.
14. Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol (2007) 23:495-517. doi:10.1146/annurev.cellbio.23.090506.123521.
15. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol (1999) 17:189-220. doi:10.1146/annurev.immunol.17.1.189.
16. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2010) 115(11):2167-76. doi:10.1182/blood-2009-08-238469.
17. Munz C. Non-cytotoxic protection by human NK cells in mucosal secondary lymphoid tissues. Eur J Immunol (2008) 38(11):2946-8. doi:10.1002/eji.200838849.
18. Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 180(12):7785-91.
19. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect (2002) 4(15):1545-58. doi:10.1016/S1286-4579(02)00038-2.
20. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol (2013) 132(3):515-25; quiz 26. doi:10.1016/j.jaci.2013.07.020.
21. Wood SM, Ljunggren HG, Bryceson YT. Insights into NK cell biology from human genetics and disease associations. Cell Mol Life Sci (2011) 68(21):3479-93. doi:10.1007/s00018-011-0799-y.
22. Tamm A, Schmidt RE. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol (1996) 157(4):1576-81.
23. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest (2012) 122(10):3769-80. doi:10.1172/JCI64837.
24. Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol (2006) 6(6):399-409. doi:10.1097/ACI.0b013e3280106b65.
25. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol (2002) 3(2):122-31. doi:10.1038/nrm732.
26. Clark R, Griffiths GM. Lytic granules, secretory lysosomes and disease. Curr Opin Immunol (2003) 15(5):516-21. doi:10.1016/S0952-7915(03)00113-4.
27. Dell'Angelica EC, Mullins C, Caplan S, Bonifacino JS. Lysosome-related organelles. FASEB J (2000) 14(10):1265-78. doi:10.1096/fj.14.10.1265.
28. Griffiths GM. Albinism and immunity: what's the link? Curr Mol Med (2002) 2(5):479-83. doi:10.2174/1566524023362258.
29. Nakata M, Kawasaki A, Azuma M, Tsuji K, Matsuda H, Shinkai Y, et al. Expression of perforin and cytolytic potential of human peripheral blood lymphocyte subpopulations. Int Immunol (1992) 4(9):1049-54. doi:10.1093/intimm/4.9.1049.
30. Salcedo TW, Azzoni L, Wolf SF, Perussia B. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol (1993) 151(5):2511-20.
31. Uellner R, Zvelebil MJ, Hopkins J, Jones J, MacDougall LK, Morgan BP, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J (1997) 16(24):7287-96. doi:10.1093/emboj/16.24.7287.
32. Griffiths GM, Isaaz S. Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor. J Cell Biol (1993) 120(4):885-96. doi:10.1083/jcb.120.4.885.
33. Bossi G, Griffiths GM. CTL secretory lysosomes: biogenesis and secretion of a harmful organelle. Semin Immunol (2005) 17(1):87-94. doi:10.1016/j.smim.2004.09.007.
34. Meade JL, de Wynter EA, Brett P, Sharif SM, Woods CG, Markham AF, et al. A family with Papillon-Lefevre syndrome reveals a requirement for cathepsin C in granzyme B activation and NK cell cytolytic activity. Blood (2006) 107(9):3665-8. doi:10.1182/blood-2005-03-1140.
35. D'Angelo ME, Bird PI, Peters C, Reinheckel T, Trapani JA, Sutton VR. Cathepsin H is an additional convertase of pro-granzyme B. J Biol Chem (2010) 285(27):20514-9. doi:10.1074/jbc.M109.094573.
36. Smyth MJ, McGuire MJ, Thia KY. Expression of recombinant human granzyme B. A processing and activation role for dipeptidyl peptidase I. J Immunol (1995) 154(12):6299-305.
37. Krzewski K, Coligan JE. Human NK cell lytic granules and regulation of their exocytosis. Front Immunol (2012) 3:335. doi:10.3389/fimmu.2012.00335.
38. Grossman WJ, Revell PA, Lu ZH, Johnson H, Bredemeyer AJ, Ley TJ. The orphan granzymes of humans and mice. Curr Opin Immunol (2003) 15(5):544-52. doi:10.1016/S0952-7915(03)00099-2.
39. Voskoboinik I, Thia MC, Fletcher J, Ciccone A, Browne K, Smyth MJ, et al. Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: a critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem (2005) 280(9):8426-34. doi:10.1074/jbc.M413303200.
40. Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol (2012) 33(8):406-12. doi:10.1016/j.it.2012.04.001.
41. Fraser SA, Karimi R, Michalak M, Hudig D. Perforin lytic activity is controlled by calreticulin. J Immunol (2000) 164(8):4150-5.
42. Masson D, Peters PJ, Geuze HJ, Borst J, Tschopp J. Interaction of chondroitin sulfate with perforin and granzymes of cytolytic T-cells is dependent on pH. Biochemistry (1990) 29(51):11229-35. doi:10.1021/bi00503a011.
43. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med (2002) 196(4):493-503. doi:10.1084/jem.20011836.
44. Cohnen A, Chiang SC, Stojanovic A, Schmidt H, Claus M, Saftig P, et al. Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage. Blood (2013) 122(8):1411-8. doi:10.1182/blood-2012-07-441832.
45. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286(5446):1957-9. doi:10.1126/science.286.5446.1957.
46. de Saint Basile G, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol (2010) 10(8):568-79. doi:10.1038/nri2803.
47. Feldmann J, Menasche G, Callebaut I, Minard-Colin V, Bader-Meunier B, Le Clainche L, et al. Severe and progressive encephalitis as a presenting manifestation of a novel missense perforin mutation and impaired cytolytic activity. Blood (2005) 105(7):2658-63. doi:10.1182/blood-2004-09-3590.
48. Ishii E, Ueda I, Shirakawa R, Yamamoto K, Horiuchi H, Ohga S, et al. Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood (2005) 105(9):3442-8. doi:10.1182/blood-2004-08-3296.
49. Katano H, Ali MA, Patera AC, Catalfamo M, Jaffe ES, Kimura H, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood (2004) 103(4):1244-52. doi:10.1182/blood-2003-06-2171.
50. Risma KA, Frayer RW, Filipovich AH, Sumegi J. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest (2006) 116(1):182-92. doi:10.1172/JCI26217.
51. Trambas C, Gallo F, Pende D, Marcenaro S, Moretta L, De Fusco C, et al. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood (2005) 106(3):932-7. doi:10.1182/blood-2004-09-3713.
52. Voskoboinik I, Dunstone MA, Baran K, Whisstock JC, Trapani JA. Perforin: structure, function, and role in human immunopathology. Immunol Rev (2010) 235(1):35-54. doi:10.1111/j.0105-2896.2010.00896.x.
53. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Arico M, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood (2006) 108(7):2316-23. doi:10.1182/blood-2006-04-015693.
54. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 110(6):1906-15. doi:10.1182/blood-2007-02-074468.
55. Chia J, Thia K, Brennan AJ, Little M, Williams B, Lopez JA, et al. Fatal immune dysregulation due to a gain of glycosylation mutation in lymphocyte perforin. Blood (2012) 119(7):1713-6. doi:10.1182/blood-2011-08-374355.
56. Clementi R, Chiocchetti A, Cappellano G, Cerutti E, Ferretti M, Orilieri E, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. Blood (2006) 108(9):3079-84. doi:10.1182/blood-2006-02-001412.
57. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr (2003) 142(3):292-6. doi:10.1067/mpd.2003.110.
58. Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet (2004) 41(2):137-44. doi:10.1136/jmg.2003.011528.
59. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther (2005) 7(1):R30-7. doi:10.1186/ar1551.
60. Voskoboinik I, Thia MC, De Bono A, Browne K, Cretney E, Jackson JT, et al. The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. J Exp Med (2004) 200(6):811-6. doi:10.1084/jem.20040776.
61. Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood (2005) 105(12):4700-6. doi:10.1182/blood-2004-12-4935.
62. Hart TC, Hart PS, Bowden DW, Michalec MD, Callison SA, Walker SJ, et al. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. J Med Genet (1999) 36(12):881-7.
63. Hewitt C, McCormick D, Linden G, Turk D, Stern I, Wallace I, et al. The role of cathepsin C in Papillon-Lefevre syndrome, prepubertal periodontitis, and aggressive periodontitis. Hum Mutat (2004) 23(3):222-8. doi:10.1002/humu.10314.
64. Toomes C, James J, Wood AJ, Wu CL, McCormick D, Lench N, et al. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat Genet (1999) 23(4):421-4. doi:10.1038/70525.
65. Pham CT, Ley TJ. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A (1999) 96(15):8627-32. doi:10.1073/pnas.96.15.8627.
66. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B, Ley TJ. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol (2004) 173(12):7277-81.
67. Badolato R, Parolini S. Novel insights from adaptor protein 3 complex deficiency. J Allergy Clin Immunol (2007) 120(4):735-41; quiz 742-3. doi:10.1016/j.jaci.2007.08.039.
68. Hermansky F, Cieslar P, Matousova O, Smetana K. Proceedings: study of albinism in relation to Hermansky-Pudlak syndrome. Thromb Diath Haemorrh (1975) 34(1):360.
69. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND, et al. A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak syndrome type 9. Am J Hum Genet (2011) 88(6):778-87. doi:10.1016/j.ajhg.2011.05.009.
70. Dell'Angelica EC. AP-3-dependent trafficking and disease: the first decade. Curr Opin Cell Biol (2009) 21(4):552-9. doi:10.1016/j.ceb.2009.04.014.
71. Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell (1999) 3(1):11-21. doi:10.1016/S1097-2765(00)80170-7.
72. Robinson MS, Bonifacino JS. Adaptor-related proteins. Curr Opin Cell Biol (2001) 13(4):444-53. doi:10.1016/S0955-0674(00)00235-0.
73. Peden AA, Oorschot V, Hesser BA, Austin CD, Scheller RH, Klumperman J. Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. J Cell Biol (2004) 164(7):1065-76. doi:10.1083/jcb.200311064.
74. Huizing M, Sarangarajan R, Strovel E, Zhao Y, Gahl WA, Boissy RE. AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. Mol Biol Cell (2001) 12(7):2075-85. doi:10.1091/mbc.12.7.2075.
75. Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, et al. Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood (2006) 107(12):4857-64. doi:10.1182/blood-2005-11-4398.
76. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood (2006) 108(1):81-7. doi:10.1182/blood-2005-11-4413.
77. Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol (2003) 4(11):1111-20. doi:10.1038/ni1000.
78. Olsen I, Bou-Gharios G, Abraham D. The activation of resting lymphocytes is accompanied by the biogenesis of lysosomal organelles. Eur J Immunol (1990) 20(10):2161-70. doi:10.1002/eji.1830201003.
79. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol (1995) 25(4):1071-9. doi:10.1002/eji.1830250432.
80. Bou-Gharios G, Moss J, Olsen I, Partridge T. Ultrastructural localization of a lysosomal enzyme in resin-embedded lymphocytes. Histochemistry (1988) 89(1):69-74. doi:10.1007/BF00496587.
81. Dent PB, Fish LA, White LG, Good RA. Chediak-Higashi syndrome. Observations on the nature of the associated malignancy. Lab Invest (1966) 15(10):1634-42.
82. White JG. The Chediak-Higashi syndrome: a possible lysosomal disease. Blood (1966) 28(2):143-56.
83. Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Curr Opin Hematol (2008) 15(1):22-9. doi:10.1097/MOH.0b013e3282f2bcce.
84. Barak Y, Nir E. Chediak-Higashi syndrome. Am J Pediatr Hematol Oncol (1987) 9(1):42-55. doi:10.1097/00043426-198721000-00008.
85. Nagle DL, Karim MA, Woolf EA, Holmgren L, Bork P, Misumi DJ, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet (1996) 14(3):307-11. doi:10.1038/ng1196-307.
86. Barbosa MD, Nguyen QA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature (1996) 382(6588):262-5. doi:10.1038/382262a0.
87. Ward DM, Griffiths GM, Stinchcombe JC, Kaplan J. Analysis of the lysosomal storage disease Chediak-Higashi syndrome. Traffic (2000) 1(11):816-22. doi:10.1034/j.1600-0854.2000.011102.x.
88. Burkhardt JK, Wiebel FA, Hester S, Argon Y. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. J Exp Med (1993) 178(6):1845-56. doi:10.1084/jem.178.6.1845.
89. Roder JC, Haliotis T, Laing L, Kozbor D, Rubin P, Pross H, et al. Further studies of natural killer cell function in Chediak-Higashi patients. Immunology (1982) 46(3):555-60.
90. Roder JC, Haliotis T, Klein M, Korec S, Jett JR, Ortaldo J, et al. A new immunodeficiency disorder in humans involving NK cells. Nature (1980) 284(5756):553-5. doi:10.1038/284553a0.
91. Klein M, Roder J, Haliotis T, Korec S, Jett JR, Herberman RB, et al. Chediak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med (1980) 151(5):1049-58. doi:10.1084/jem.151.5.1049.
92. Katz P, Zaytoun AM, Fauci AS. Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest (1982) 69(6):1231-8. doi:10.1172/JCI110562.
93. Haliotis T, Roder J, Klein M, Ortaldo J, Fauci AS, Herberman RB. Chediak-Higashi gene in humans I. Impairment of natural-killer function. J Exp Med (1980) 151(5):1039-48. doi:10.1084/jem.151.5.1039.
94. Brahmi Z. Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome. Hum Immunol (1983) 6(1):45-52. doi:10.1016/0198-8859(83)90072-1.
95. Abo T, Roder JC, Abo W, Cooper MD, Balch CM. Natural killer (HNK-1+) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J Clin Invest (1982) 70(1):193-7. doi:10.1172/JCI110592.
96. Targan SR, Oseas R. The "lazy" NK cells of Chediak-Higashi syndrome. J Immunol (1983) 130(6):2671-4.
97. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol (1995) 154(11):6122-31.
98. Stinchcombe JC, Page LJ, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. Traffic (2000) 1(5):435-44. doi:10.1034/j.1600-0854.2000.010508.x.
99. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol (2008) 8(9):713-25. doi:10.1038/nri2381.
100. Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A (1999) 96(26):15062-7. doi:10.1073/pnas.96.26.15062.
101. Orange JS, Harris KE, Andzelm MM, Valter MM, Geha RS, Strominger JL. The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci U S A (2003) 100(24):14151-6. doi:10.1073/pnas.1835830100.
102. Vyas YM, Mehta KM, Morgan M, Maniar H, Butros L, Jung S, et al. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J Immunol (2001) 167(8):4358-67.
103. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood (2009) 114(13):2657-66. doi:10.1182/blood-2009-01-201632.
104. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med (2005) 202(7):1001-12. doi:10.1084/jem.20051143.
105. Liu D, Bryceson YT, Meckel T, Vasiliver-Shamis G, Dustin ML, Long EO. Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity (2009) 31(1):99-109. doi:10.1016/j.immuni.2009.05.009.
106. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol (2004) 173(6):3653-9.
107. Mentlik AN, Sanborn KB, Holzbaur EL, Orange JS. Rapid lytic granule convergence to the MTOC in natural killer cells is dependent on dynein but not cytolytic commitment. Mol Biol Cell (2010) 21(13):2241-56. doi:10.1091/mbc.E09-11-0930.
108. Riteau B, Barber DF, Long EO. Vav1 phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization. J Exp Med (2003) 198(3):469-74. doi:10.1084/jem.20021995.
109. Kishimoto TK, Hollander N, Roberts TM, Anderson DC, Springer TA. Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell (1987) 50(2):193-202. doi:10.1016/0092-8674(87)90215-7.
110. Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Ann N Y Acad Sci (2012) 1250:50-5. doi:10.1111/j.1749-6632.2011.06389.x.
111. Kohl S, Loo LS, Schmalstieg FS, Anderson DC. The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J Immunol (1986) 137(5):1688-94.
112. Kohl S, Springer TA, Schmalstieg FC, Loo LS, Anderson DC. Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. J Immunol (1984) 133(6):2972-8.
113. Lau YL, Low LC, Jones BM, Lawton JW. Defective neutrophil and lymphocyte function in leucocyte adhesion deficiency. Clin Exp Immunol (1991) 85(2):202-8. doi:10.1111/j.1365-2249.1991.tb05705.x.
114. James AM, Hsu HT, Dongre P, Uzel G, Mace EM, Banerjee PP, et al. Rapid activation receptor-or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling. Blood (2013) 121(14):2627-37. doi:10.1182/blood-2012-06-437012.
115. Castriconi R, Dondero A, Cantoni C, Della Chiesa M, Prato C, Nanni M, et al. Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood (2007) 109(11):4873-81. doi:10.1182/blood-2006-08-038760.
116. Moser M, Legate KR, Zent R, Fassler R. The tail of integrins, talin, and kindlins. Science (2009) 324(5929):895-9. doi:10.1126/science.1163865.
117. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med (2008) 14(3):325-30. doi:10.1038/nm1722.
118. Ye F, Petrich BG. Kindlin: helper, co-activator, or booster of talin in integrin activation? Curr Opin Hematol (2011) 18(5):356-60. doi:10.1097/MOH.0b013e3283497f09.
119. Feigelson SW, Grabovsky V, Manevich-Mendelson E, Pasvolsky R, Shulman Z, Shinder V, et al. Kindlin-3 is required for the stabilization of TCR-stimulated LFA-1:ICAM-1 bonds critical for lymphocyte arrest and spreading on dendritic cells. Blood (2011) 117(26):7042-52. doi:10.1182/blood-2010-12-322859.
120. Jurk K, Schulz AS, Kehrel BE, Rapple D, Schulze H, Mobest D, et al. Novel integrin-dependent platelet malfunction in siblings with leukocyte adhesion deficiency-III (LAD-III) caused by a point mutation in FERMT3. Thromb Haemost (2010) 103(5):1053-64. doi:10.1160/TH09-10-0689.
121. Malinin NL, Zhang L, Choi J, Ciocea A, Razorenova O, Ma YQ, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med (2009) 15(3):313-8. doi:10.1038/nm.1917.
122. Manevich-Mendelson E, Feigelson SW, Pasvolsky R, Aker M, Grabovsky V, Shulman Z, et al. Loss of kindlin-3 in LAD-III eliminates LFA-1 but not VLA-4 adhesiveness developed under shear flow conditions. Blood (2009) 114(11):2344-53. doi:10.1182/blood-2009-04-218636.
123. McDowall A, Svensson L, Stanley P, Patzak I, Chakravarty P, Howarth K, et al. Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. Blood (2010) 115(23):4834-42. doi:10.1182/blood-2009-08-238709.
124. Robert P, Canault M, Farnarier C, Nurden A, Grosdidier C, Barlogis V, et al. A novel leukocyte adhesion deficiency III variant: kindlin-3 deficiency results in integrin-and nonintegrin-related defects in different steps of leukocyte adhesion. J Immunol (2011) 186(9):5273-83. doi:10.4049/jimmunol.1003141.
125. Svensson L, Howarth K, McDowall A, Patzak I, Evans R, Ussar S, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med (2009) 15(3):306-12. doi:10.1038/nm.1931.
126. Gruda R, Brown AC, Grabovsky V, Mizrahi S, Gur C, Feigelson SW, et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood (2012) 120(19):3915-24. doi:10.1182/blood-2012-02-410795.
127. Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci (2013) 1285:26-43. doi:10.1111/nyas.12049.
128. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol (2010) 10(3):182-92. doi:10.1038/nri2724.
129. Parolini O, Berardelli S, Riedl E, Bello-Fernandez C, Strobl H, Majdic O, et al. Expression of Wiskott-Aldrich syndrome protein (WASP) gene during hematopoietic differentiation. Blood (1997) 90(1):70-5.
130. Stewart DM, Treiber-Held S, Kurman CC, Facchetti F, Notarangelo LD, Nelson DL. Studies of the expression of the Wiskott-Aldrich syndrome protein. J Clin Invest (1996) 97(11):2627-34. doi:10.1172/JCI118712.
131. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell (1994) 79(5):following922.
132. Orange JS, Stone KD, Turvey SE, Krzewski K. The Wiskott-Aldrich syndrome. Cell Mol Life Sci (2004) 61(18):2361-85. doi:10.1007/s00018-004-4086-z.
133. Lim RP, Misra A, Wu Z, Thanabalu T. Analysis of conformational changes in WASP using a split YFP. Biochem Biophys Res Commun (2007) 362(4):1085-9. doi:10.1016/j.bbrc.2007.08.124.
134. Hemsath L, Dvorsky R, Fiegen D, Carlier MF, Ahmadian MR. An electrostatic steering mechanism of Cdc42 recognition by Wiskott-Aldrich syndrome proteins. Mol Cell (2005) 20(2):313-24. doi:10.1016/j.molcel.2005.08.036.
135. Higgs HN, Pollard TD. Activation by Cdc42 and PIP(2) of Wiskott-Aldrich syndrome protein (WASp) stimulates actin nucleation by Arp2/3 complex. J Cell Biol (2000) 150(6):1311-20. doi:10.1083/jcb.150.6.1311.
136. Prehoda KE, Scott JA, Mullins RD, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science (2000) 290(5492):801-6. doi:10.1126/science.290.5492.801.
137. Rohatgi R, Ho HY, Kirschner MW. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol (2000) 150(6):1299-310. doi:10.1083/jcb.150.6.1299.
138. Symons M, Derry JM, Karlak B, Jiang S, Lemahieu V, McCormick F, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell (1996) 84(5):723-34. doi:10.1016/S0092-8674(00)81050-8.
139. Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood (2004) 104(2):436-43. doi:10.1182/blood-2003-07-2621.
140. Orange JS, Ramesh N, Remold-O'Donnell E, Sasahara Y, Koopman L, Byrne M, et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A (2002) 99(17):11351-6. doi:10.1073/pnas.162376099.
141. Orange JS, Roy-Ghanta S, Mace EM, Maru S, Rak GD, Sanborn KB, et al. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. J Clin Invest (2011) 121(4):1535-48. doi:10.1172/JCI44862.
142. Carlin LM, Evans R, Milewicz H, Fernandes L, Matthews DR, Perani M, et al. A targeted siRNA screen identifies regulators of Cdc42 activity at the natural killer cell immunological synapse. Sci Signal (2011) 4(201):ra81. doi:10.1126/scisignal.2001729.
143. Sinai P, Nguyen C, Schatzle JD, Wulfing C. Transience in polarization of cytolytic effectors is required for efficient killing and controlled by Cdc42. Proc Natl Acad Sci U S A (2010) 107(26):11912-7. doi:10.1073/pnas.0913422107.
144. Lanzi G, Moratto D, Vairo D, Masneri S, Delmonte O, Paganini T, et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med (2013) 209(1):29-34. doi:10.1084/jem.20110896.
145. Garcia E, Jones GE, Machesky LM, Anton IM. WIP: WASP-interacting proteins at invadopodia and podosomes. Eur J Cell Biol (2012) 91(11-12):869-77. doi:10.1016/j.ejcb.2012.06.002.
146. Anton IM, Jones GE, Wandosell F, Geha R, Ramesh N. WASP-interacting protein (WIP): working in polymerisation and much more. Trends Cell Biol (2007) 17(11):555-62. doi:10.1016/j.tcb.2007.08.005.
147. Krzewski K, Chen X, Orange JS, Strominger JL. Formation of a WIP-, WASp-, actin-, and myosin IIA-containing multiprotein complex in activated NK cells and its alteration by KIR inhibitory signaling. J Cell Biol (2006) 173(1):121-32. doi:10.1083/jcb.200509076.
148. Krzewski K, Chen X, Strominger JL. WIP is essential for lytic granule polarization and NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 105(7):2568-73. doi:10.1073/pnas.0711593105.
149. Cote JF, Vuori K. Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. J Cell Sci (2002) 115(Pt 24):4901-13. doi:10.1242/jcs.00219.
150. Cote JF, Vuori K. GEF what? Dock180 and related proteins help Rac to polarize cells in new ways. Trends Cell Biol (2007) 17(8):383-93. doi:10.1016/j.tcb.2007.05.001.
151. Meller N, Merlot S, Guda C. CZH proteins: a new family of Rho-GEFs. J Cell Sci (2005) 118(Pt 21):4937-46. doi:10.1242/jcs.02671.
152. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 124(6):1289-302.e4. doi:10.1016/j.jaci.2009.10.038.
153. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med (2009) 361(21):2046-55. doi:10.1056/NEJMoa0905506.
154. Su HC. Dedicator of cytokinesis 8 (DOCK8) deficiency. Curr Opin Allergy Clin Immunol (2010) 10(6):515-20. doi:10.1097/ACI.0b013e32833fd718.
155. Ham H, Guerrier S, Kim J, Schoon RA, Anderson EL, Hamann MJ, et al. Dedicator of cytokinesis 8 interacts with talin and Wiskott-Aldrich syndrome protein to regulate NK cell cytotoxicity. J Immunol (2013) 190(7):3661-9. doi:10.4049/jimmunol.1202792.
156. Mizesko MC, Banerjee PP, Monaco-Shawver L, Mace EM, Bernal WE, Sawalle-Belohradsky J, et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol (2013) 131(3):840-8. doi:10.1016/j.jaci.2012.12.1568.
157. Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med (2011) 208(11):2305-20. doi:10.1084/jem.20110345.
158. Randall KL, Lambe T, Johnson AL, Treanor B, Kucharska E, Domaschenz H, et al. Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. Nat Immunol (2009) 10(12):1283-91. doi:10.1038/ni.1820.
159. Harada Y, Tanaka Y, Terasawa M, Pieczyk M, Habiro K, Katakai T, et al. DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses. Blood (2012) 119(19):4451-61. doi:10.1182/blood-2012-01-407098.
160. Di Paolo G, Pellegrini L, Letinic K, Cestra G, Zoncu R, Voronov S, et al. Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin. Nature (2002) 420(6911):85-9. doi:10.1038/nature01147.
161. Ling K, Doughman RL, Firestone AJ, Bunce MW, Anderson RA. Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. Nature (2002) 420(6911):89-93. doi:10.1038/nature01082.
162. Mace EM, Zhang J, Siminovitch KA, Takei F. Elucidation of the integrin LFA-1-mediated signaling pathway of actin polarization in natural killer cells. Blood (2010) 116(8):1272-9. doi:10.1182/blood-2009-12-261487.
163. Cannon JL, Burkhardt JK. The regulation of actin remodeling during T-cell-APC conjugate formation. Immunol Rev (2002) 186:90-9. doi:10.1034/j.1600-065X.2002.18609.x.
164. Eng EW, Bettio A, Ibrahim J, Harrison RE. MTOC reorientation occurs during FcgammaR-mediated phagocytosis in macrophages. Mol Biol Cell (2007) 18(7):2389-99. doi:10.1091/mbc.E06-12-1128.
165. Etienne-Manneville S. Cdc42-the centre of polarity. J Cell Sci (2004) 117(Pt 8):1291-300. doi:10.1242/jcs.01115.
166. Pulecio J, Petrovic J, Prete F, Chiaruttini G, Lennon-Dumenil AM, Desdouets C, et al. Cdc42-mediated MTOC polarization in dendritic cells controls targeted delivery of cytokines at the immune synapse. J Exp Med (2010) 207(12):2719-32. doi:10.1084/jem.20100007.
167. Stowers L, Yelon D, Berg LJ, Chant J. Regulation of the polarization of T cells toward antigen-presenting cells by Ras-related GTPase CDC42. Proc Natl Acad Sci U S A (1995) 92(11):5027-31. doi:10.1073/pnas.92.11.5027.
168. Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM. Centrosome polarization delivers secretory granules to the immunological synapse. Nature (2006) 443(7110):462-5. doi:10.1038/nature05071.
169. Chen X, Trivedi PP, Ge B, Krzewski K, Strominger JL. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. Proc Natl Acad Sci U S A (2007) 104(15):6329-34. doi:10.1073/pnas.0611655104.
170. Graham DB, Cella M, Giurisato E, Fujikawa K, Miletic AV, Kloeppel T, et al. Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics. J Immunol (2006) 177(4):2349-55.
171. Sancho D, Nieto M, Llano M, Rodriguez-Fernandez JL, Tejedor R, Avraham S, et al. The tyrosine kinase PYK-2/RAFTK regulates natural killer (NK) cell cytotoxic response, and is translocated and activated upon specific target cell recognition and killing. J Cell Biol (2000) 149(6):1249-62. doi:10.1083/jcb.149.6.1249.
172. Banerjee PP, Pandey R, Zheng R, Suhoski MM, Monaco-Shawver L, Orange JS. Cdc42-interacting protein-4 functionally links actin and microtubule networks at the cytolytic NK cell immunological synapse. J Exp Med (2007) 204(10):2305-20. doi:10.1084/jem.20061893.
173. Kanwar N, Wilkins JA. IQGAP1 involvement in MTOC and granule polarization in NK-cell cytotoxicity. Eur J Immunol (2011) 41(9):2763-73. doi:10.1002/eji.201040444.
174. Gorman JA, Babich A, Dick CJ, Schoon RA, Koenig A, Gomez TS, et al. The cytoskeletal adaptor protein IQGAP1 regulates TCR-mediated signaling and filamentous actin dynamics. J Immunol (2012) 188(12):6135-44. doi:10.4049/jimmunol.1103487.
175. Sanchez-Ruiz J, Mejias R, Garcia-Belando M, Barber DF, Gonzalez-Garcia A. Ral GTPases regulate cell-mediated cytotoxicity in NK cells. J Immunol (2011) 187(5):2433-41. doi:10.4049/jimmunol.1003089.
176. Tuli A, Thiery J, James AM, Michelet X, Sharma M, Garg S, et al. Arf-like GTPase Arl8b regulates lytic granule polarization and natural killer cell-mediated cytotoxicity. Mol Biol Cell (2013) 24(23):3721-35. doi:10.1091/mbc.E13-05-0259.
177. Kurowska M, Goudin N, Nehme NT, Court M, Garin J, Fischer A, et al. Terminal transport of lytic granules to the immune synapse is mediated by the kinesin-1/Slp3/Rab27a complex. Blood (2012) 119(17):3879-89. doi:10.1182/blood-2011-09-382556.
178. Stinchcombe JC, Salio M, Cerundolo V, Pende D, Arico M, Griffiths GM. Centriole polarisation to the immunological synapse directs secretion from cytolytic cells of both the innate and adaptive immune systems. BMC Biol (2011) 9:45. doi:10.1186/1741-7007-9-45.
179. Brown AC, Oddos S, Dobbie IM, Alakoskela JM, Parton RM, Eissmann P, et al. Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. PLoS Biol (2011) 9(9):e1001152. doi:10.1371/journal.pbio.1001152.
180. Rak GD, Mace EM, Banerjee PP, Svitkina T, Orange JS. Natural killer cell lytic granule secretion occurs through a pervasive actin network at the immune synapse. PLoS Biol (2011) 9(9):e1001151. doi:10.1371/journal.pbio.1001151.
181. Heissler SM, Manstein DJ. Nonmuscle myosin-2: mix and match. Cell Mol Life Sci (2013) 70(1):1-21. doi:10.1007/s00018-012-1002-9.
182. Eddinger TJ, Meer DP. Myosin II isoforms in smooth muscle: heterogeneity and function. Am J Physiol Cell Physiol (2007) 293(2):C493-508. doi:10.1152/ajpcell.00131.2007.
183. Ricketson D, Johnston CA, Prehoda KE. Multiple tail domain interactions stabilize nonmuscle myosin II bipolar filaments. Proc Natl Acad Sci U S A (2010) 107(49):20964-9. doi:10.1073/pnas.1007025107.
184. Sellers JR. Myosins: a diverse superfamily. Biochim Biophys Acta (2000) 1496(1):3-22. doi:10.1016/S0167-4889(00)00005-7.
185. Even-Ram S, Yamada KM. Of mice and men: relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease. Cell Adh Migr (2007) 1(3):152-5. doi:10.4161/cam.1.3.5089.
186. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, Panza E, et al. MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) (2003) 82(3):203-15. doi:10.1097/01.md.0000076006.64510.5c.
187. Ito M, Tanabe F, Sato A, Ishida E, Takami Y, Shigeta S. Inhibition of natural killer cell-mediated cytotoxicity by ML-9, a selective inhibitor of myosin light chain kinase. Int J Immunopharmacol (1989) 11(2):185-90. doi:10.1016/0192-0561(89)90070-2.
188. Andzelm MM, Chen X, Krzewski K, Orange JS, Strominger JL. Myosin IIA is required for cytolytic granule exocytosis in human NK cells. J Exp Med (2007) 204(10):2285-91. doi:10.1084/jem.20071143.
189. Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, et al. Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood (2011) 118(22):5862-71. doi:10.1182/blood-2011-03-344846.
190. Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, et al. Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse. J Immunol (2009) 182(11):6969-84. doi:10.4049/jimmunol.0804337.
191. Liu D, Meckel T, Long EO. Distinct role of rab27a in granule movement at the plasma membrane and in the cytosol of NK cells. PLoS One (2010) 5(9):e12870. doi:10.1371/journal.pone.0012870.
192. Wood SM, Meeths M, Chiang SC, Bechensteen AG, Boelens JJ, Heilmann C, et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood (2009) 114(19):4117-27. doi:10.1182/blood-2009-06-225359.
193. Lee MT, Mishra A, Lambright DG. Structural mechanisms for regulation of membrane traffic by rab GTPases. Traffic (2009) 10(10):1377-89. doi:10.1111/j.1600-0854.2009.00942.x.
194. Pfeffer S, Aivazian D. Targeting Rab GTPases to distinct membrane compartments. Nat Rev Mol Cell Biol (2004) 5(11):886-96. doi:10.1038/nrm1500.
195. Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet (2000) 25(2):173-6. doi:10.1038/76024.
196. Sanal O, Ersoy F, Tezcan I, Metin A, Yel L, Menasche G, et al. Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity. J Clin Immunol (2002) 22(4):237-43. doi:10.1023/A:1016045026204.
197. Jahn R, Scheller RH. SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol (2006) 7(9):631-43. doi:10.1038/nrm2002.
198. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol (2006) 6(12):919-29. doi:10.1038/nri1980.
199. Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science (2009) 323(5913):474-7. doi:10.1126/science.1161748.
200. Rudd E, Goransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gurgey A, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet (2006) 43(4):e14. doi:10.1136/jmg.2005.035253.
201. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet (2005) 14(6):827-34. doi:10.1093/hmg/ddi076.
202. Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature (2012) 490(7419):201-7. doi:10.1038/nature11320.
203. Cote M, Menager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest (2009) 119(12):3765-73. doi:10.1172/JCI40732.
204. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell (2003) 115(4):461-73. doi:10.1016/S0092-8674(03)00855-9.
205. zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet (2009) 85(4):482-92. doi:10.1016/j.ajhg.2009.09.005.
206. Maul-Pavicic A, Chiang SC, Rensing-Ehl A, Jessen B, Fauriat C, Wood SM, et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A (2011) 108(8):3324-9. doi:10.1073/pnas.1013285108.
207. Feske S, Picard C, Fischer A. Immunodeficiency due to mutations in ORAI1 and STIM1. Clin Immunol (2010) 135(2):169-82. doi:10.1016/j.clim.2010.01.011.
208. Fukuda M. Versatile role of Rab27 in membrane trafficking: focus on the Rab27 effector families. J Biochem (2005) 137(1):9-16. doi:10.1093/jb/mvi002.
209. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am J Med (1978) 65(4):691-702. doi:10.1016/0002-9343(78)90858-6.
210. Meeths M, Bryceson YT, Rudd E, Zheng C, Wood SM, Ramme K, et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer (2010) 54(4):563-72. doi:10.1002/pbc.22357.
211. Menasche G, Ho CH, Sanal O, Feldmann J, Tezcan I, Ersoy F, et al. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest (2003) 112(3):450-6. doi:10.1172/JCI200318264.
212. Strom M, Hume AN, Tarafder AK, Barkagianni E, Seabra MC. A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport. J Biol Chem (2002) 277(28):25423-30. doi:10.1074/jbc.M202574200.
213. Hume AN, Collinson LM, Hopkins CR, Strom M, Barral DC, Bossi G, et al. The leaden gene product is required with Rab27a to recruit myosin Va to melanosomes in melanocytes. Traffic (2002) 3(3):193-202. doi:10.1034/j.1600-0854.2002.030305.x.
214. Gazit R, Aker M, Elboim M, Achdout H, Katz G, Wolf DG, et al. NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome. Blood (2007) 109(10):4306-12. doi:10.1182/blood-2006-09-047159.
215. Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, et al. Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr (1994) 125(6 Pt 1):886-95. doi:10.1016/S0022-3476(05)82003-7.
216. Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol (1998) 38(2 Pt 2):295-300. doi:10.1016/S0190-9622(98)70568-7.
217. Plebani A, Ciravegna B, Ponte M, Mingari MC, Moretta L. Interleukin-2 mediated restoration of natural killer cell function in a patient with Griscelli syndrome. Eur J Pediatr (2000) 159(9):713-4. doi:10.1007/s004310000501.
218. Haddad EK, Wu X, Hammer JA III, Henkart PA. Defective granule exocytosis in Rab27a-deficient lymphocytes from Ashen mice. J Cell Biol (2001) 152(4):835-42. doi:10.1083/jcb.152.4.835.
219. Stinchcombe JC, Barral DC, Mules EH, Booth S, Hume AN, Machesky LM, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol (2001) 152(4):825-34. doi:10.1083/jcb.152.4.825.
220. Holt O, Kanno E, Bossi G, Booth S, Daniele T, Santoro A, et al. Slp1 and Slp2-a localize to the plasma membrane of CTL and contribute to secretion from the immunological synapse. Traffic (2008) 9(4):446-57. doi:10.1111/j.1600-0854.2008.00714.x.
221. Menasche G, Menager MM, Lefebvre JM, Deutsch E, Athman R, Lambert N, et al. A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T cells and participates to cytotoxic granule secretion. Blood (2008) 112(13):5052-62. doi:10.1182/blood-2008-02-141069.
222. Menager MM, Menasche G, Romao M, Knapnougel P, Ho CH, Garfa M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol (2007) 8(3):257-67. doi:10.1038/ni1431.
223. Katano H, Cohen JI. Perforin and lymphohistiocytic proliferative disorders. Br J Haematol (2005) 128(6):739-50. doi:10.1111/j.1365-2141.2004.05305.x.
224. Rohr J, Beutel K, Maul-Pavicic A, Vraetz T, Thiel J, Warnatz K, et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica (2010) 95(12):2080-7. doi:10.3324/haematol.2010.029389.
225. Santoro A, Cannella S, Bossi G, Gallo F, Trizzino A, Pende D, et al. Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis. J Med Genet (2006) 43(12):953-60. doi:10.1136/jmg.2006.041863.
226. Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell (2005) 16(2):731-41. doi:10.1091/mbc.E04-10-0923.
227. Shirakawa R, Higashi T, Tabuchi A, Yoshioka A, Nishioka H, Fukuda M, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem (2004) 279(11):10730-7. doi:10.1074/jbc.M309426200.
228. Tang BL, Low DY, Hong W. Syntaxin 11: a member of the syntaxin family without a carboxyl terminal transmembrane domain. Biochem Biophys Res Commun (1998) 245(2):627-32. doi:10.1006/bbrc.1998.8490.
229. Prekeris R, Klumperman J, Scheller RH. Syntaxin 11 is an atypical SNARE abundant in the immune system. Eur J Cell Biol (2000) 79(11):771-80. doi:10.1078/0171-9335-00109.
230. Arneson LN, Brickshawana A, Segovis CM, Schoon RA, Dick CJ, Leibson PJ. Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J Immunol (2007) 179(6):3397-401.
231. D'Orlando O, Zhao F, Kasper B, Orinska Z, Muller J, Hermans-Borgmeyer I, et al. Syntaxin 11 is required for NK and CD8(+) T-cell cytotoxicity and neutrophil degranulation. Eur J Immunol (2013) 43(1):194-208. doi:10.1002/eji.201142343.
232. Kogl T, Muller J, Jessen B, Schmitt-Graeff A, Janka G, Ehl S, et al. Hemophagocytic lymphohistiocytosis in syntaxin-11-deficient mice: T-cell exhaustion limits fatal disease. Blood (2013) 121(4):604-13. doi:10.1182/blood-2012-07-441139.
233. Dabrazhynetskaya A, Ma J, Guerreiro-Cacais AO, Arany Z, Rudd E, Henter JI, et al. Syntaxin 11 marks a distinct intracellular compartment recruited to the immunological synapse of NK cells to colocalize with cytotoxic granules. J Cell Mol Med (2012) 16(1):129-41. doi:10.1111/j.1582-4934.2011.01280.x.
234. Valdez AC, Cabaniols JP, Brown MJ, Roche PA. Syntaxin 11 is associated with SNAP-23 on late endosomes and the trans-Golgi network. J Cell Sci (1999) 112(Pt 6):845-54.
235. Krzewski K, Gil-Krzewska A, Watts J, Stern JN, Strominger JL. VAMP4-and VAMP7-expressing vesicles are both required for cytotoxic granule exocytosis in NK cells. Eur J Immunol (2011) 41(11):3323-9. doi:10.1002/eji.201141582.
236. Marcet-Palacios M, Odemuyiwa SO, Coughlin JJ, Garofoli D, Ewen C, Davidson CE, et al. Vesicle-associated membrane protein 7 (VAMP-7) is essential for target cell killing in a natural killer cell line. Biochem Biophys Res Commun (2008) 366(3):617-23. doi:10.1016/j.bbrc.2007.11.079.
237. Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood (2010) 116(15):2635-43. doi:10.1182/blood-2010-05-282541.